Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsBruce Strober, MD, PhD, FAAD
Clinical ProfessorAbout
Research
Publications
2025
Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial
Terui T, Okubo Y, Kobayashi S, Morita A, Imafuku S, Tada Y, Abe M, Strober B, Gooderham M, Hara Y, Zhang W, Shimauchi J, Yaguchi M, Kimura T, Ogawa R, Amouzadeh H, Murakami M. Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial. Dermatology And Therapy 2025, 1-4. PMID: 41387650, DOI: 10.1007/s13555-025-01583-z.Peer-Reviewed Original ResearchPhase 3 studyPalmoplantar pustulosisWeeks of treatmentPatient-reported qualityJapanese patientsTreatment optionsTopical treatmentSide effectsResponse to topical treatmentPatient-reported quality of lifeSafety of apremilastOral treatment optionsPhase 3 trialSoft stoolClinical severityApremilastPlaceboPatientsQuality of lifePustulosisWeeksTreatmentConsistent with previous studiesOptionsNasopharyngitisLaboratory monitoring in patients with moderate to severe plaque psoriasis
Fenkel J, Osborne J, Armstrong A, Strober B, Gold L, Cameron M, Lebwohl M. Laboratory monitoring in patients with moderate to severe plaque psoriasis. Journal Of Dermatological Treatment 2025, 36: 2583227. PMID: 41346021, DOI: 10.1080/09546634.2025.2583227.Peer-Reviewed Original ResearchConceptsSmall molecule therapiesSevere plaque psoriasisLaboratory monitoringPlaque psoriasisComorbid conditionsLaboratory monitoring guidelinesIndividual patient's clinical characteristicsPatient clinical characteristicsClinical characteristicsLaboratory valuesPrimary care physiciansPsoriatic arthritisLiver diseasePsoriasisPatientsTherapyCardiovascular diseaseClinical practiceMood disordersMonitoring guidelinesCare physiciansTherapeutic classesComorbiditiesExpert recommendationsDermatologistsApremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial
Terui T, Okubo Y, Kobayashi S, Morita A, Imafuku S, Tada Y, Abe M, Strober B, Gooderham M, Zhang W, Shimauchi J, Yaguchi M, Kimura T, Ogawa R, Amouzadeh H, Murakami M. Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial. Journal Of The European Academy Of Dermatology And Venereology 2025 PMID: 41297955, DOI: 10.1111/jdv.70166.Peer-Reviewed Original ResearchPhase 3 studyPhase 3 trialPalmoplantar pustulosisAdverse eventsJapanese patientsTotal scoreDouble-blind phasePalmoplantar Pustulosis AreaFatal adverse eventsProportion of patientsActive treatment phaseApremilast groupDouble-blindPlacebo groupPlacebo-ControlledStudy drugPrimary endpointRandomized patientsSafety profileTreatment optionsApremilastChronic dermatitisPlaceboSeverity scorePPPASIJoint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors
Blauvelt A, Strober B, Eakin G, McCormick Howard L, Langan C, van de Kerkhof P, Puig L, Lebwohl M, Romiti R, Armstrong A, Choon S, Ramessur R, Gelfand J, Merola J, Winthrop K, Torres T. Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors. Journal Of The American Academy Of Dermatology 2025 PMID: 41260526, DOI: 10.1016/j.jaad.2025.11.033.Peer-Reviewed Original ResearchIL-23 inhibitorsInternational Psoriasis CouncilIL-23Psoriasis patientsIL-17Latent TB infectionJoint position statementTB infectionTreated with IL-17National Psoriasis Foundation Medical BoardPosition statementTreatment of psoriasis patientsIL-23 blockersConcomitant immunosuppressive therapyInfection to active diseaseRoutine testingTB-endemic areasNational Psoriasis FoundationImmunosuppressive therapyActive diseaseLatent tuberculosisPsoriasis expertsPsoriasisPatientsEndemic areasComparison of All-Cause Mortality in Generalized Pustular Psoriasis and Plaque Psoriasis: A Systematic Review and Meta-Analysis
Strober B, Puig L, Lebwohl M, Lakshminarasimhan B, Khan S, Pillai N, Kappelhoff B, Weatherill A, Warren R. Comparison of All-Cause Mortality in Generalized Pustular Psoriasis and Plaque Psoriasis: A Systematic Review and Meta-Analysis. Dermatology And Therapy 2025, 1-14. PMID: 41205050, DOI: 10.1007/s13555-025-01584-y.Peer-Reviewed Original ResearchAll-Cause MortalityGeneral populationPlaque psoriasisPlaque psoriasis patientsPooled hazard ratioHazard ratioMeta-analysesEffect sizeGPP patientsPustular psoriasisPsoriasis patientsReview of unpublished dataIntroduction of targeted treatmentsEffective biological therapiesPatients' all-cause mortalityGeneralized pustular psoriasisRandom-effects modelLife-threatening complicationsAssociated with mortalityAll-CauseStudy screeningNeutrophilic inflammatory diseasesData extractionSystematic reviewBiologic therapyBimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials
Strober B, Boehncke W, Krueger J, Magnolo N, Vender R, Warren R, López Pinto J, Kavanagh S, Hoepken B, Gisondi P. Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials. Dermatology And Therapy 2025, 15: 3633-3650. PMID: 41060492, PMCID: PMC12619882, DOI: 10.1007/s13555-025-01557-1.Peer-Reviewed Original ResearchSevere plaque psoriasisOpen-label extensionPost Hoc AnalysisBE VIVIDPlaque psoriasisNail involvementDisease durationBE SUREConfidence intervalsDisease severityEfficacy of biologicsPhase 3 trialSubgroup of patientsEfficacy of biological treatmentsProportion of patientsLong-term efficacyNon-responder imputationLong-term treatmentClinical responseSkin clearanceBimekizumabHigher RatesBiological exposurePatient subgroupsClinical trialsIn Memoriam Dr. Wayne Peter Francis Gulliver, MD, FRCPC March 4, 1958, to September 5, 2025
Strober B. In Memoriam Dr. Wayne Peter Francis Gulliver, MD, FRCPC March 4, 1958, to September 5, 2025. Journal Of The American Academy Of Dermatology 2025 DOI: 10.1016/j.jaad.2025.10.060.Peer-Reviewed Original ResearchEstablishing consensus on defining failure of topical therapy in psoriasis: Recommendations from the International Psoriasis Council
Strober B, Blauvelt A, van de Kerkhof P, Asawanonda P, Chandra R, Gonzalez-Cantero A, Gonzalez C, Matlock B, Maul J, Rob F, Torres T, Skov L. Establishing consensus on defining failure of topical therapy in psoriasis: Recommendations from the International Psoriasis Council. Journal Of The American Academy Of Dermatology 2025, 94: 372-375. PMID: 40945737, DOI: 10.1016/j.jaad.2025.08.116.Peer-Reviewed Original ResearchSystemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy
Burshtein J, Bunick C, Vleugels R, Armstrong A, Golant A, Schlesinger T, Strober B, Song E, Gold L, Lebwohl M. Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy. Journal Of Investigative Dermatology 2025, 145: 2947-2949. PMID: 40914897, DOI: 10.1016/j.jid.2025.08.002.Peer-Reviewed Original Research62300 Long-Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response in Patients with Moderate to Severe Psoriasis Treated with Risankizumab: 3 Year Results from the CorEvitas Psoriasis Registry
Armstrong A, Ferris L, Duffin K, Sima A, Eckmann T, Beeghly A, Garg V, Bialik B, Patel M, Strober B. 62300 Long-Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response in Patients with Moderate to Severe Psoriasis Treated with Risankizumab: 3 Year Results from the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2025, 93: ab244. DOI: 10.1016/j.jaad.2025.05.970.Peer-Reviewed Original Research